+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

The Classified Progression in Binding Modes of Autotaxin (ATX) Inhibitors

Volume 7 - Issue 3

Hongrui Lei1, Fang Jia1, Ming Guo1, Dajun Zhang2* and Xin Zhai1*2

  • Author Information Open or Close
    • 1Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, PR China
    • 2Shenyang Medical College, PR China

    *Corresponding author: Xin Zhai, Shenyang Pharmaceutical University, Shenyang 110016, PR China, China

    *Corresponding author: Dajun Zhang, Shenyang Medical College, Shenyang 110034, PR China, China

Received: July 25, 2018;   Published: July 30, 2018

DOI: 10.26717/BJSTR.2018.07.001496

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Autotaxin (ATX) is a secreted enzyme which hydrolyzes lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and choline. The ATX-LPA axis has attracted increasing interest recently for both ATX and LPA are involved in various pathological conditions such as tumor progression and metastasis, fibrotic diseases, arthritis, autoimmune diseases and obesity. Thus, great efforts have been devoted in identifying synthetic ATX inhibitors as new agents for treating various diseases including cancer and fibrotic diseases. Herein, this mini review mainly focused on the binding modes of the reported ATX inhibitors and their indications correspondingly.

Keywords: ATX; ATX-LPA Axis; ATX Inhibitors; Binding Mode; Indications

Keywords: ENPPs: Ectonucleotide Pyrophosphatases/Phosphodiesterases; lysoPLD: Lysophospholipase D; SMB: Somatomedin B; PDE: Phosphodiesterase; NUC: Nuclease; Thr210: Threonine Residue; IPF: Idiopathic Pulmonary Fibrosis

Abstract | Introduction | Binding Modes of Reported ATX Inhibitors | The Main Indications of ATX Inhibitors | Perspective | Acknowledgments | References |